[177Lu]Lu-DOTA-TATE

DRUG4 trials

Sponsors

Novartis Pharmaceuticals

Conditions

Extensive Stage Small Cell Lung CancerGastroenteropancreatic Neuroendocrine Tumor (GEP-NET)GlioblastomaMetastatic Neuroendocrine Prostate CancerSomatostatin Receptor Positive (SSTR+)

Phase 1

A Dose Finding Study of [177Lu]Lu-DOTA-TATE in Newly Diagnosed Glioblastoma in Combination With Standard of Care and in Recurrent Glioblastoma as a Single Agent.

Active, not recruitingNCT05109728

Novartis PharmaceuticalsGlioblastoma

Start: 2022-05-10End: 2027-07-31Updated: 2026-03-16

A Study of [177Lu]Lu-DOTA-TATE in Newly Diagnosed ES-SCLC Patients in Combination With Carboplatin, Etoposide and Atezolizumab

Active, not recruitingNCT05142696

Novartis PharmaceuticalsExtensive Stage Small Cell Lung Cancer

Start: 2022-07-13End: 2029-03-23Updated: 2026-03-17

NEPC Study: An Exploratory Safety and Efficacy Study With PSMA, SSTR2 and GRPR Targeted Radioligand Therapy in Metastatic Neuroendocrine Prostate Cancer.

Active, not recruitingNCT06379217

Novartis PharmaceuticalsMetastatic Neuroendocrine Prostate Cancer

Start: 2024-07-29End: 2026-08-27Updated: 2026-03-11

Phase 3

Study to Evaluate the Efficacy and Safety of [177Lu]Lu-DOTA-TATE in Patients With Grade 1 and Grade 2 Advanced GEP-NET

RecruitingNCT06784752

Novartis PharmaceuticalsGastroenteropancreatic Neuroendocrine Tumor (GEP-NET), Somatostatin Receptor Positive (SSTR+)

Start: 2025-05-30End: 2034-01-05Target: 240Updated: 2026-03-06

Related Papers

RTID-05. TRIAL IN PROGRESS: DOSE-FINDING STUDY AND EVALUATION OF [177LU]LU-DOTA-TATE IN COMBINATION WITH STANDARD OF CARE IN NEWLY DIAGNOSED GLIOBLASTOMA AND AS A SINGLE AGENT IN RECURRENT GLIOBLASTOMA

Neuro-Oncology2022-11-011 citations